M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in
multiple parts to establish the safety, tolerability and Pharmacokinetic/Pharmacodynamic
(PK/PD) profile (with and without food) and early signs of efficacy of M1774 as monotherapy
and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.